Jupiter Life Line (JLHL) delivered robust financial results for the June quarter, with consolidated net sales reaching ₹410.98 crore, representing an 18.23% year-on-year growth. The company's standalone net sales also grew 18.18% Y-o-Y to ₹328.49 crore, as reported by The Economic Times. This strong revenue performance comes as the company continues its aggressive expansion strategy to scale healthcare capacity from approximately 1,700 beds to 2,900 beds.
Jupiter Life Line's Dombivli hospital posted a ₹9.5 crore Ebitda loss in the June quarter, as reported by The Economic Times. The 500-bed facility completed its first full quarter of operations with occupancy at around 25-30%. Management has retained its guidance for the facility to reach Ebitda breakeven in about 1.5-2 years, while noting that patient footfall has been steadily improving month-on-month. The hospital is being commissioned in phases, with around 200 beds already operational and fit-outs completed for another 100 beds.
Jupiter Life Line is pursuing an aggressive expansion strategy that will significantly scale its healthcare capacity. According to The Economic Times, the company has a 500-bed facility in Pune, a 300-bed Mira-Bhayandar project, and a 400-bed BKC hospital in the pipeline. Cumulatively, these projects will increase the company's total capacity from approximately 1,700 beds to 2,900 beds. The Dombivli hospital is part of this expansion, with the facility coming up in phases and around 200 beds currently operational.
Jupiter Life Line (JLHL) shares were trading at ₹307.45 as of 3:31 p.m. on August 27, 2026, on NSE/BSE. According to market data, the stock carries a medium quality and momentum rating, though its expensive valuations suggest caution for investors. The current trading price reflects market sentiment around the company's expansion strategy and operational challenges at its newer facilities, while the strong quarterly results provide a positive backdrop for the healthcare provider's growth trajectory.
The company is witnessing growing institutional interest as it pursues its expansion strategy. As reported by The Economic Times, among top mutual funds, SBI Healthcare Opportunities Fund had ₹155.44 crore invested, equivalent to 2.88% of its AUM, while HDFC Multi Cap Fund held ₹98.24 crore or 0.48% of AUM. HDFC Pharma and Healthcare Fund had ₹72.10 crore invested, representing 2.45% of AUM, and HDFC Small Cap Fund held ₹56.63 crore, or 0.14% of AUM. During July, HDFC Multicap and smallcap funds added the stock fresh into their portfolios, while SBI Healthcare Opportunities and HDFC Multicap Regular fund increased their holdings.
